PMV Pharmaceuticals, Inc
PMVPPMV Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies that modulate p53, a tumor suppressor protein involved in preventing cancer. The company is dedicated to advancing precision medicines for cancer patients with p53 mutations, leveraging its proprietary p53 reactivation platform.
Company News
PMV Pharmaceuticals announced a leadership transition with Laurie Stelzer, a director since 2020, appointed as the new Board Chair, succeeding Rich Heyman effective June 4, 2026. Stelzer brings over 25 years of senior finance and business development experience in biopharmaceuticals. The transition occurs as the company continues enrollment in it...
PMV Pharmaceuticals reported positive Phase 2 interim data from its PYNNACLE trial evaluating rezatapopt for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutations, achieving a 50% overall response rate among 48 evaluable patients. The company received FDA Orphan Drug Designation and plans to submit a New Drug Application in Q1 20...
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a f...
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
Related Companies
